 result random trial idarubicin cytosin arabinosid daunorubicin cytosin arabinosid adult patient myelogen leukemia idarubicin idr new anthracyclin differ parent compound delet methoxi group posit chromophor ring minor structur modif result lipophil compound uniqu metabolit prolong plasma half-lif vitro vivo antileukemia activ activ acut myelogen leukemia aml consecut adult patient age diseas singl institut studi idr combin cytosin arabinosid ara-c standard therapi daunorubicin dnr ara-c trial o'brien-flem multipl design period inspect data specif patient access point accrual patient arm analysi patient idr/ara-c superior respons standard therapi patient complet remiss former arm patient latter logist regress analysi factor complet respons treatment idr/ara-c signific advantag patient high initi white blood cell count treatment dnr/ara-c degre marrow aplasia arm nonhematolog toxic overal surviv patient idr/ara-c arm month month dnr/ara-c arm median follow-up year idr/ara-c standard therapi dnr/ara-c adult patient age aml